These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 16051951

  • 1. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer.
    Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M, Wada H.
    J Clin Oncol; 2005 Aug 01; 23(22):4999-5006. PubMed ID: 16051951
    [Abstract] [Full Text] [Related]

  • 2. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
    Imaizumi M, Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan).
    Lung Cancer; 2005 Jul 01; 49(1):85-94. PubMed ID: 15949594
    [Abstract] [Full Text] [Related]

  • 3. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials.
    Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M.
    J Clin Oncol; 2004 Oct 01; 22(19):3860-7. PubMed ID: 15326194
    [Abstract] [Full Text] [Related]

  • 4. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
    Nakagawa T, Tanaka F, Takata T, Matsuoka K, Miyahara R, Otake Y, Yanagihara K, Fukushimab M, Wada H.
    J Surg Oncol; 2002 Oct 01; 81(2):87-92. PubMed ID: 12355409
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy of postoperative adjuvant therapy for resected non-small cell lung cancer--an evidence-based review].
    Tanaka F, Wada H.
    Gan To Kagaku Ryoho; 2006 Mar 01; 33(3):300-6. PubMed ID: 16531708
    [Abstract] [Full Text] [Related]

  • 6. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
    Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K, Akazawa K, Abe O.
    J Clin Oncol; 2005 Apr 01; 23(10):2172-84. PubMed ID: 15800310
    [Abstract] [Full Text] [Related]

  • 7. Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer.
    Hotta K, Matsuo K, Kiura K, Ueoka H, Tanimoto M.
    Curr Opin Oncol; 2006 Mar 01; 18(2):144-50. PubMed ID: 16462183
    [Abstract] [Full Text] [Related]

  • 8. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
    Miyoshi T, Kondo K, Toba H, Yoshida M, Fujino H, Kenzaki K, Sakiyama S, Takehisa M, Tangoku A.
    Anticancer Res; 2007 Mar 01; 27(4C):2641-8. PubMed ID: 17695427
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant chemotherapy for non-small-cell lung cancer.
    Pisters KM.
    Clin Adv Hematol Oncol; 2003 Sep 01; 1(9):533-7. PubMed ID: 16258445
    [Abstract] [Full Text] [Related]

  • 10. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature.
    Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, Sculier JP.
    Lung Cancer; 2005 Jul 01; 49(1):13-23. PubMed ID: 15949586
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. The Japan Clinical Oncology Group.
    Ohta M, Tsuchiya R, Shimoyama M, Sawamura K, Mori T, Miyazawa N, Suemasu K, Watanabe Y, Tomita M, Terashima M.
    J Thorac Cardiovasc Surg; 1993 Oct 01; 106(4):703-8. PubMed ID: 8412266
    [Abstract] [Full Text] [Related]

  • 12. [Adjuvant chemotherapy for non-small cell lung cancer].
    Otake Y, Tanaka F, Wada H, Hitomi S.
    Gan To Kagaku Ryoho; 1997 Aug 01; 24(10):1245-51. PubMed ID: 9279343
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of p53 status in non-small cell lung cancer in correlation with postoperative adjuvant therapy.
    Hanaoka N, Tanaka F, Wada H.
    Thorac Cardiovasc Surg; 2002 Dec 01; 50(6):355-9. PubMed ID: 12457313
    [Abstract] [Full Text] [Related]

  • 14. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
    Früh M, Rolland E, Pignon JP, Seymour L, Ding K, Tribodet H, Winton T, Le Chevalier T, Scagliotti GV, Douillard JY, Spiro S, Shepherd FA.
    J Clin Oncol; 2008 Jul 20; 26(21):3573-81. PubMed ID: 18640938
    [Abstract] [Full Text] [Related]

  • 15. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.
    Johnson BE, Rabin MS.
    Clin Cancer Res; 2005 Jul 01; 11(13 Pt 2):5022s-5026s. PubMed ID: 16000607
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
    Pisters KM, Le Chevalier T.
    J Clin Oncol; 2005 May 10; 23(14):3270-8. PubMed ID: 15886314
    [Abstract] [Full Text] [Related]

  • 17. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer.
    Tanaka F, Otake Y, Yanagihara K, Yamada T, Miyahara R, Kawano Y, Li M, Inui K, Wada H.
    Br J Cancer; 2001 Jan 10; 84(2):263-9. PubMed ID: 11161386
    [Abstract] [Full Text] [Related]

  • 18. Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer.
    Park JH, Lee CT, Lee HW, Baek HJ, Zo JI, Shim YM.
    Eur J Cardiothorac Surg; 2005 Jun 10; 27(6):1086-91. PubMed ID: 15896623
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.